According to the news from chinastarmarket.cn on the 16th, AIM Vaccine announced that two candidates of COVID-19 mRNA vaccine were approved for clinical trials in Pakistan. One targeting SARS-nCoV-2 mutant is approved for Phase I clinical trial, while the other targeting original COVID-19 virus is approved for Phase III clinical trial of sequential booster vaccination. Besides, AIM Vaccine's bivalent mRNA vaccine against Omicron BA.5, first of its kind in China, has entered IND stage. Its previous experimental data showed high rates of prevention and good results of safety and immunogenicity.